Nectin-4, already validated as a therapeutic target through the antibody–drug conjugate enfortumab vedotin, approved for advanced urothelial carcinoma (Heath and Rosenberg, 2021) has further spurred the development of NECTIN4-directed CAR-T cells. Here, NECTIN4 is linked to urothelial carcinoma.